Together, these data from the six paired models suggest that evolution of SCLC following chemotherapy (with or without etoposide) results in resistance to topoisomerase II inhibitors and the in vivo study in CDX17P implicates sGC signalling in this resistance. This evidence concerns the gene SGCB and small cell lung carcinoma.